The Insights Series is conducted as a series of interviews and conversations with internationally renowned scientific experts along with Cereno leadership, who share their knowledge and insights to provide a greater understanding of the company's intensified focus on further developing the product portfolio.

“The understanding of cardiovascular disease and the important need for innovation is a topic close to our experts’ hearts. Their solid backgrounds in cardiology plays a central role in our continued work to develop preventive medicine to treat cardiovascular disease and this series will provide valuable insights that we are happy to share,” says Sten R. Sörensen.

Together with the leading healthcare company Abbott, Cereno is in involved in a Phase II study with the lead drug candidate CS1, an HDAC inhibitor, using Abbott's CardioMEMS technology - and in the first video, you will meet Philip B. Adamson, Chief Medical Officer, Heart Failure Division, Divisional Vice President at Abbott, USA, in a conversation with Cereno’s Chief Executive Officer, Sten R. Sörensen and Chief Medical Officer, Björn Dahlöf about CS1 - PAH Clinical Trial Design. 

The video series will be available on Cereno’s website and social media.

For further information, please contact:

Josefine Göranson, Head of IR & Communications
Phone: +46 704 92 35 63
Email: info@cerenoscientific.com

http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.